Aptar Pharma says new eDevices will speed up regulatory approval

By Natalie Morrison

- Last updated on GMT

Related tags: Asthma, Chronic obstructive pulmonary disease, Pharmacology

Aptar Pharma says its new eDevices can help companies gain quicker regulatory approval for their nasal drug products without having to re-do clinical trials.

The firm gave in-PharmaTechnologist an exclusive first look at its newly expanded measured dosage tech at last week’s Pharmapack Europe 2012.

Joachim Koerner, VP of eDevice R&D, prescription division, said the platform – which consists of dose display e-Dose Counter, and dose restrictor e-Lockout – is the type of controlled self-administration measure regulators are leaning towards at the moment.

He said: “More and more regulators are asking for safety features added to products, for instance to prevent overdosing, like our e-Lockout system does.

“For example in the US the regulators ask for dose counters or indicators when you try to get new asthma COPD (chronic obstructive pulmonary disease) inhalers or other pressurized metered-dose inhalers (pDMI) into the market.

“We meet the regulator recommendations for nasal spray devices and pDMIs and also pain treatment.”

He added that the platform technology offering is highly customisable, and will therefore save clients the time and expense of trial do-overs.

“We have a close link to the primary package,”​ he said. “We know exactly what the performance of the primary package is and do not touch the spray performance characteristics of the primary package while adapting our eDevice.

“That means there is no need to re-do clinical studies and so they save a lot of time and money.”

Related news

Show more

Related products

show more

The battle of performance in pharma production

The battle of performance in pharma production

Telstar Life Science Solutions | 26-Mar-2019 | Case Study

Telstar case study. Discover how a versatile freeze-dryer automatic loading & unloading systemDiscover how a versatile freeze-dryer automatic loading...

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Fill Release at the Right Time in the Right Place

Fill Release at the Right Time in the Right Place

Gelita AG | 19-Sep-2018 | Technical / White Paper

From rapid release in the stomach for e.g. analgesics to enteric release for fills with unpleasant aftertaste – GELITA delivers the respective gelatine...

Accelerate your supply chain as pressures intensify

Accelerate your supply chain as pressures intensify

William Reed | 17-Sep-2018 | Technical / White Paper

Food, Drink and Non-Food manufacturers are under pressure. Range reviews, massive retail mergers, the backlash against plastic packaging and the ongoing...

Related suppliers